Laxmi Dental Q4 FY26 results: Board meet May 21, 2026

What the company has announced

Laxmi Dental Limited has scheduled a meeting of its Board of Directors on Thursday, May 21, 2026. The stated purpose is to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company filed this intimation with the stock exchange on May 18, 2026, citing Regulation 29(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For investors tracking the Healthcare and Dental space, board meetings that approve audited results often act as key information events because they set the reference point for audited annual numbers and the final quarter performance. The company has also reiterated the process around trading-window closure and reopening, which is standard under insider trading norms.

Board meeting: key details

The board meeting is specifically linked to approving audited results for Q4 FY26 and FY26. The disclosure sets out the meeting date, the period under review, and the regulation under which the notice has been issued.

Trading window closure and reopening

The trading window has been closed since April 01, 2026, according to the disclosure. The company said the trading window will reopen 48 hours after the declaration of results. This is aligned with typical compliance practice for companies when unpublished price-sensitive information is in process.

For market participants, the reopening timeline matters mainly for employees, insiders, and connected persons covered under the company’s code of conduct, but it also signals the expected sequencing around when results are made public.

Where the results will be published

Laxmi Dental said the approved results will be made available on its official website after the board approves them. This is consistent with standard disclosure practice where financial statements and related documents are posted on the corporate website following stock exchange submission.

Filing signatory and corporate identity details

The intimation was signed by Suman Saha, Company Secretary and Compliance Officer (ICSI Membership Number: A33035). The disclosure also notes that Laxmi Dental Limited was formerly known as Laxmi Dental Export Private Limited and is headquartered in Mumbai.

Analyst estimates: two sets of projections cited

The provided text includes analyst consensus estimates that project Laxmi Dental’s Q4 FY26 revenue at INR 82 crore, representing about 9% year-on-year growth, with PAT estimated at INR 22 crore, up about 22% versus the same quarter in FY25. It also cites an expected EBITDA margin of about 26.8% for the quarter.

Separately, the same source also cites a different estimate range for Q4 FY26, projecting revenue at INR 280-310 crore, PAT at INR 43-52 crore, and EBITDA margin at 20-22%. Since both sets appear in the provided material, investors should treat them as distinct estimates as presented, rather than a single unified consensus.

Stock context mentioned alongside the result event

The source text places the upcoming audited results in the context of Laxmi Dental’s market performance and key reference levels. It states the stock was at INR 1,200, compared with a 52-week high of INR 1,620, and a 1-year return of -16%.

While price moves around results can vary, these figures frame why the audited FY26 print can matter for sentiment and near-term positioning.

Snapshot from prior disclosed financials: Q2 FY26 and FY25

Alongside the board-meeting notice, the provided material also includes financial information for earlier periods, including Q2 FY26 (quarter ended September 30, 2025) and FY25 (year ended March 31, 2025). The consolidated and standalone financials are presented in INR millions in the source; the table below converts them into INR crore (1 crore = 10 million) for comparability.

Auditor review note and exceptional item details mentioned

The text states that the Statutory Auditor, MSKA & Associates, carried out a limited review of consolidated and standalone unaudited financial results for the quarter and half year ended September 30, 2025. The auditor’s conclusion is described as unmodified, with no qualifications or concerns highlighted.

The material also describes an exceptional item in FY25 linked to a gain on sale of an investment property on May 7, 2024. The sale consideration is stated as INR 10.10 crore, with a book value of INR 0.71 crore and a gain before tax of INR 9.39 crore. The net exceptional gain after tax is stated as revised to INR 7.03 crore for FY25 due to a tax rate change under Section 115BAA.

IPO proceeds utilisation and investment actions cited

The provided information includes IPO proceeds utilisation details: total IPO proceeds of INR 128.17 crore, with INR 64.12 crore utilised up to September 30, 2025 and INR 64.05 crore unutilised and invested in fixed deposits. It also lists utilisation heads including borrowings repayment (stated as fully utilised), investments in subsidiaries (partially utilised), capital expenditure for machinery (INR 4.60 crore utilised and INR 38.91 crore unutilised), and general corporate purposes (INR 31.94 crore utilised).

On investments and acquisitions, it mentions an additional investment of USD 1 million in Laxmi Dental Lab USA INC in April 2025, acquisition of additional shares in Bizdent Devices Private Limited via rights issue for INR 40.92 crore in April 2025, and an investment in joint venture IDBG Al Dent Global Private Limited of INR 2.00 crore during Q2 FY26.

Why the May 21 board meeting matters

The May 21, 2026 meeting is the formal step for approving audited standalone and consolidated results for the quarter and year ended March 31, 2026. For shareholders, audited full-year results are the base document for evaluating annual performance, and they often serve as the anchor for discussions on profitability quality, margins, and the effect of any one-offs.

The disclosure also sets clear timelines on trading-window reopening and confirms that results will be published on the company website after approval. The next concrete milestone in the sequence is the board’s decision and the subsequent publication of the audited numbers.